Flow matching for antibody CDR sequence–structure co-design
Peer-reviewed| Поле | Значение |
|---|---|
| Authors | NR |
| Year | 2025 |
| Venue / status | Peer-reviewed journal; Cell Systems (Q1) |
| DOI | 10.1016/j.cels.2025.101270 |
| URL | https://doi.org/10.1016/j.cels.2025.101270 |
| Preprint URL | NR |
| Tools | FlowDesign |
Задача и claimed novelty
| Поле | Значение |
|---|---|
| Main biological task | Antibody CDR sequence–structure co-design with flow matching |
| Claimed novelty | NR |
Архитектура
| Поле | Значение |
|---|---|
| Model architecture | Flow matching with improved structural priors |
| Input representation | NR |
| Encoder / decoder | NR |
| Generative state | CDR sequence and structure |
| Conditioning | CDR design masks and structural priors |
| Sampling | NR |
Training
| Поле | Значение |
|---|---|
| Objectives / losses | NR |
| Dataset | NR |
| Preprocessing | NR |
Inference
NR
Baselines и retrospective benchmarks
| Поле | Значение |
|---|---|
| Baselines | NR |
| Retrospective | NR |
Prospective experimental validation
| Поле | Значение |
|---|---|
| Prospective | Reported improved binding affinity and neutralizing potency versus Ibalizumab; workload-specific details require paper extraction |
| Tested designs | Ibalizumab-focused HIV design study; exact tested count: NR here |
| Success criterion | Reported improved binding affinity and neutralizing potency versus Ibalizumab; workload-specific details require paper extraction |
| Main results | Reported improved binding affinity and neutralizing potency versus Ibalizumab; workload-specific details require paper extraction |
Limitations
Narrow prospective target context; lack of verified public code blocks independent pilot; must separate predicted and measured gains.
Что статья показывает
- Reported improved binding affinity and neutralizing potency versus Ibalizumab; workload-specific details require paper extraction
Чего статья не показывает
- Predicted confidence, likelihood, pLDDT, docking or developability scores are not experimental affinity.
Размеченные утверждения
| Утверждение | Тип | Локатор |
|---|---|---|
| Flow matching for antibody CDR sequence–structure co-design | Interpretation | DOI/URL from landscape matrix |
| Publication status: Peer-reviewed journal; Cell Systems (Q1) | Author-reported | landscape matrix, publication status column |
Review queue
- Bibliographic title must be verified against the PDF.
- Official repository/service not verified.
Source-grounded разбор статьи
Исследовательский вопрос
[MATRIX]Antibody CDR sequence–structure co-design with flow matching
Утверждения и поддержка evidence
[MATRIX]Claimed novelty: NR
[INTERPRETATION]Статья не «доказывает» общее преимущество метода вне своего экспериментального дизайна.
Что представленный evidence не поддерживает
- Predicted confidence, likelihood, pLDDT, docking or developability scores are not experimental affinity.
Ограничения, признанные авторами
[MATRIX]Narrow prospective target context; lack of verified public code blocks independent pilot; must separate predicted and measured gains.
Дополнительные ограничения интерпретации
NRПока Methods/SI не прочитаны, нельзя утверждать split leakage, точные гиперпараметры и полноту ablation.